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Abstract: The etiology of the intestinal disease Crohn’s disease involves genetic factors as 
well as ill-defined environmental agents. Several genetic variants linked to this disease are 
associated with autophagy, a process that is critical for proper responses to viral infections. 
While a role for viruses in this disease remains speculative, accumulating evidence indicate 
that this possibility requires serious consideration. In this review, we will examine the 
three-way relationship between viruses, autophagy genes, and Crohn’s disease and discuss 
how host-pathogen interactions can mediate complex inflammatory disorders. 
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1. Introduction 
Crohn’s disease is a major form of inflammatory bowel disease that affects as many as 1 in 500 
individuals [1]. Family and twin studies have demonstrated a strong heritable component to the disease 
that is the subject of intense research [2]. The age of onset is frequently in the second decade of life, 
and most patients progress to a relapsing disease characterized by abdominal pain, bloody diarrhea, 
vomiting, and weight loss. Crohn’s disease is distinguished from other types of inflammatory bowel 
disease such as ulcerative colitis in that the inflammation is often discontinuous, transmural, and can 
involve both the small intestine and colon [3,4]. Anti-inflammatory or immuno-suppressive drugs such 
as those that target TNFα can sometimes be effective, but surgical removal of inflamed regions is 
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common despite medical intervention [5]. Additionally, significant complications such as colorectal 
cancer, malnutrition, and opportunistic infections in patients have been attributed to either chronic 
inflammation or aggressive medical treatment. A better understanding of disease origin and 
mechanism is necessary to improve the prognosis of this serious disorder. 
Since the disease mechanism at some level involves an aberrant response to intestinal bacteria, there 
has been a significant attempt at identifying a bacterial pathogen that causes Crohn’s   
disease [6,7]. However, the difficulty in differentiating cause and effect of inflammation has prevented 
the identification of a single bacterial species that is clearly a trigger rather than an opportunistic 
infection  [6,8]. Alternatively, it is possible that the genetic background favors the outgrowth of 
harmful bacteria that are already present in the gastrointestinal tract. Dramatic experiments in mice 
with Klebsiella pneumoniae, Proteus mirabilis, and adherent-invasive Escherichia coli (AIEC) have 
demonstrated that the increased presence of certain endogenous bacteria can induce intestinal disease 
[6,9,10]. This hypothesis is supported by the observation that the composition of intestinal bacterial 
species is altered in inflammatory bowel disease patients [11,12]. It is also possible that, instead of an 
outgrowth of certain pathogenic bacteria, harmless commensal species facilitate disease specifically in 
a genetically susceptible background. This concept is best demonstrated in dnKO mice (Tgfβ 
dominant  negative x IL-10R2  knockout) in which common Bacteroides  species  invoke  fulminant 
colitis [13]. These studies collectively indicate that there are certain bacteria that can mediate disease, 
but that they are unlikely to be sufficient since these species are ubiquitous. 
What are the genetic risk factors that could have such profound effects on the intestinal environment 
and host-bacteria interactions? Large-scale genetic studies of Crohn’s disease patients have successfully 
identified many susceptibility loci. The most recent meta-analysis of genome-wide screens confirmed 
the existence of 71 susceptibility loci [14], and many more are predicted to exist [15]. A striking 
example of the success  of these studies is the association of several genes directly or indirectly 
implicated in the autophagy pathway. Autophagy is a major degradative pathway of the cell with 
several critical functions in innate and adaptive immunity [16]. As such, the relationship between 
autophagy and Crohn’s disease is an exciting area of research and progress. However, finer genetic 
mapping is necessary for some of these susceptibility loci that are near but not within the coding region 
of a gene. Moreover, statistical association of any gene with Crohn’s disease must be functionally 
validated, especially since most of the gene variants that have been identified confer a minimal degree 
of risk. As genome or exome sequences from patients become available, rare mutations that are 
inevitably missed by current approaches will be revealed [17]. Nevertheless, these genetic studies have 
provided critical evidence that Crohn’s disease is associated with numerous variants rather than a 
single mutation, and further characterization of susceptibility genes will surely increase our 
understanding of this disease and mucosal immunity in general. 
While it is essential to identify gene variants and commensal bacteria that mediate intestinal disease, 
these approaches alone will be insufficient to explain the origin of Crohn’s disease. Many genes have 
unexpected cell-type specific functions that must be empirically derived. This concern is particularly 
germane for genes implicated in autophagy [16]. Additionally, there is a poorly understood 
environmental component to the disease that may precede or accelerate the inflammatory response to 
commensal bacteria. In light of recent evidence, this review will focus on the three-way relationship 
between viruses, autophagy genes, and Crohn’s disease (Figure 1). We will first examine the Viruses 2011, 3   
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epidemiological evidence for a viral etiology of inflammatory bowel disease, a topic that has received 
inadequate attention due to the lack of available data. Then we will discuss the link between the 
autophagy pathway and Crohn’s disease including an unexpected interaction between a viral infection 
and the autophagy gene ATG16L1. Finally, we will revisit the role of commensal bacteria in the 
context of these recent findings and discuss why viruses and autophagy must continue to be examined 
specifically in Crohn’s disease. 
Figure 1. Overview of the three-way relationship discussed in this review. The relationship 
between autophagy and viruses (1) is the subject of this Special Issue of Viruses. The 
current evidence that viruses influence the course of Crohn’s disease (2) will be discussed 
in Section 2. Genes that participate in the autophagy pathway have been linked to Crohn’s 
disease (3) and will be discussed in Section 3. Finally, recent evidence in a mouse model 
linking all three (4) will be discussed in Section 4. The endoscopic image of the colon was 
taken from a Crohn’s disease patient and shows sigmoid pseudopolyps with cobblestone-
like polyps. 
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2. Viruses and Inflammatory Bowel Disease 
2.1. Evidence for an Infectious Trigger 
Epidemiological studies have left no doubt that there is an environmental component to Crohn’s 
disease. Despite the identification of many genetic susceptibility loci, they collectively account for 
only a third of the disease risk [14]. Twin studies provide further confirmation that the genetic 
component is an important but incomplete explanation [2]. Additionally, as seen with other auto-
inflammatory or autoimmune disorders, the incidence of inflammatory bowel disease has increased 
over the years in parallel with industrialization, with the highest incidences in Northern Europe and 
North America [1,18]. This geographical divide may be due to a differential exposure to certain classes 
of pathogens. While industrialization has encouraged the spread of certain food-borne viruses and 
bacteria  [19], parasitic infections are still common in developing nations [20].  This correlative 
evidence is supported by both clinical studies and experiments in mice demonstrating that infection 
with a helminth such as Trichuris species protects against inflammatory bowel disease by suppressing 
inflammatory T cells [20-23]. Therefore, pathogens represent one group of environmental factors that 
are likely to be a key component to inflammatory bowel diseases such as Crohn’s disease. 
2.2. Viruses Associated With Inflammatory Bowel Disease 
Experiments reported in the 70s implicated a transmissible agent that passes through a 0.2 µm  
filter [24], but enthusiasm waned as subsequent studies failed to correlate specific viruses with the 
disease [25]. However, the techniques used to detect viruses have become significantly more sensitive, 
and several viruses have been linked by more recent association studies [26-30]. These viruses do not 
display exclusive association with Crohn’s disease and could be opportunistic or irrelevant as seen 
with cytomegalovirus (CMV). Infection with this β-herpesvirus is frequently asymptomatic and has an 
estimated prevalence between 30–100% worldwide [31]. CMV has received the  attention  of 
gastroenterologists because it can cause colitis in immuno-compromised individuals such as those 
infected with HIV or transplant recipients [32,33]. CMV reactivation from latency can be detected in 
inflammatory bowel disease patients, though reactivation is likely being triggered by inflammation 
rather than the other way around [34]. Similarly, the  γ-herpesvirus Epstein-Barr virus (EBV) is highly 
prevalent and has been associated with inflammatory bowel disease because of its presence in the 
colonic tissue of patients [35]. A recent clinical study found that viral replication and proliferating B 
cells were increased in IBD patients [36]. Other herpesviruses have also been detected in patients, but 
like CMV and EBV, evidence of causality is lacking [30].  
In a case report of an individual diagnosed with ulcerative colitis, Parvovirus B19 was detected in 
diseased tissue [27]. Parvovirus B19 is a non-enveloped single-stranded DNA virus that causes 
erythema infectiosum in children and is primarily spread by respiratory droplets [37]. Infection by this 
virus is common, but the suspicious presence in the inflamed intestinal mucosa described in this case 
report is novel. Another common virus that has been associated with inflammatory bowel disease are 
noroviruses, which are the leading cause of non-bacterial acute gastroenteritis [38]. The ease with 
which noroviruses spread in crowded areas and adapt to host immunity make them a natural suspect in 
intestinal diseases that are becoming more common like Crohn’s disease and irritable bowel   Viruses 2011, 3   
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syndrome [39-42]. Analyses of patient history suggest that acute gastroenteritis (not necessarily viral) 
precedes diagnosis of inflammatory bowel disease in some individuals [43-46], and there is evidence 
that noroviruses exacerbate inflammatory bowel disease [25,28]. Noroviruses are the only viruses that 
have been associated with Crohn’s disease in an animal model [47], a finding that will be discussed 
further. Higher power clinical studies will help determine if there is a genuine association between the 
above viruses and inflammatory bowel disease, but it is equally important to take advantage of 
advances in deep sequencing and bioinformatics to search for new viruses. The emphasis may initially 
be on viruses that infect the mammalian host, but these approaches are also likely to address the 
currently unknown role of the diverse set of bacteriophages present in the intestine [48]. 
2.3. Crohn’s Disease Genes and Viruses 
Cigarette smoking, non-steroidal anti-inflammatory drugs (NSAIDs), and diet are all non-infectious 
environmental factors that can influence the course of inflammatory bowel disease [49-51]. Yet an 
infectious provocateur has remained the most satisfying environmental factor since pathogens are a 
strong evolutionary force that may have led to the selection of gene variants associated with 
inflammatory disorders [52,53]. The autophagy-related gene IRGM has undergone significant changes 
during evolution, and natural variants of this gene contribute to the response against Mycobacterium 
tuberculosis [54,55]. IRGM has been independently associated with Crohn’s disease [56]. Therefore, it 
is possible that certain aspects of the autophagy pathway are evolutionarily plastic and critical for a 
balanced immune response in the face of infectious threats that change over time.  
Most of the genes associated with Crohn’s disease have known immune functions. NOD2 was the 
first to be identified and encodes a cytosolic pattern recognition receptor (PRR) that induces NF-κB 
activation and cytokine expression in the presence of muramyl dipeptide (MDP), a derivative of 
bacterial peptidoglycan [57-59]. The mutations associated with Crohn’s disease are found in the 
Leucine rich repeat (LRR) domain that is essential for recognition of MDP [60]. Although it is unclear 
how these mutations contribute to intestinal disease and whether Nod2 binds MDP directly, these 
findings reinforce an important role for bacteria in Crohn’s disease. One group has found that   
single-stranded viral RNA can also bind Nod2, leading to its translocation to the mitochondria where it 
binds MAVS and signals type I interferon (IFN) production [61]. With the expanding role of Nod2,  
it will be important to validate these results and determine if Crohn’s disease mutations disrupt   
this pathway. 
Many of the other genes linked to Crohn’s disease have been identified by genome wide association 
studies (GWAS) [14]. GWAS analyze variants, typically single nucleotide polymorphisms (SNPs), 
distributed throughout the genome and identify those that are represented more frequently in 
individuals with a trait or disease of interest. A number of these genes associated with Crohn’s disease 
are important for T cells. The SNPs in the IL-23R gene region display particularly strong association 
and significantly reduce the risk of developing Crohn’s disease [62]. IL-23 directs the differentiation of 
TH17 cells, pro-inflammatory T cells that produce IL-17, IL-22, and IL-21 [63]. Inflammatory bowel 
disease patients have high levels of IL-23, IL-17, IL-21, and IL-22 producing cells in their intestine 
[64-68]  and TH17 cells are potent mediators of intestinal inflammation in mouse models  of 
experimental colitis [69-71]. It is not difficult to imagine a scenario in which a viral infection would Viruses 2011, 3   
 
 
1286 
alter the total number and function of a subset of T cells that mediate chronic inflammatory disease. 
Although this concept has not been demonstrated specifically for TH17 cells and intestinal disease, 
observations made in T-bet/Eomes-deficient mice and patients infected with hepatitis C virus (HCV) 
and respiratory syncytial virus (RSV) indicate that it is a possibility [72-75]. 
The above description of NOD2 and IL23R is far from complete, and there are many more putative 
susceptibility genes that have a more obvious role in antiviral immunity such as IRF1 [14]. Again, 
many of these genes await further confirmation of their association with Crohn’s disease, and their 
significance in influencing disease course is uncertain. Before describing susceptibility genes related to 
the autophagy pathway, one more gene is worth mentioning in relation to viruses and Crohn’s disease. 
Unlike many of the gene variants examined in GWAS, the polymorphism in the fucosyl transferase 
gene FUT2 linked to Crohn’s disease leads to a coding change with a clear effect [14,76]. Individuals 
that are homozygous for this ‘non-secretor’ variant do not secrete blood group antigens on epithelial 
surfaces and are  significantly protected from symptomatic infection by certain norovirus strains 
[41,77].  Thus, this variant of FUT2  links differential susceptibility to viral infection with risk of 
developing Crohn’s disease. These genetic associations do not necessarily implicate viruses but are 
compatible with a viral etiology or pathogen triggers in general. 
3. Autophagy Genes and Susceptibility Loci: A Link Between Crohn’s Disease and Infectious 
Agents?  
Autophagy is best known as a highly conserved cell survival mechanism that promotes general 
homeostasis by degrading damaged or unwanted proteins and organelles and providing nutrients 
during prolonged periods of starvation [78]. Since this pathway has been implicated in the maintenance 
of many immune cells including B and T cells  [79-83], autophagy-deficiency could alter host 
immunity prior to the presence of a pathogen.  Autophagy  requires the generation of a de novo  
double-membraned vesicle (autophagosome) that sequesters and degrades encapsulated cargo via the 
eventual fusion with the lysosome. Intracellular pathogens are frequently  observed  within 
autophagosomes, and through a process often referred to as xenophagy, can be targeted for subsequent 
degradation much like an unwanted protein or organelle [16]. This simple mechanism does not always 
reflect what is occurring in vivo. Although cell culture experiments initially indicated that ICP34.5 
encoded by herpes simplex virus (HSV-1) inhibits autophagy to evade intracellular degradation [84], 
later work established that this inhibition is important in vivo for evading antigen presentation and 
activating CD4+ T cells [85,86].  Also,  the pathogenesis of Sindbis virus infection of the central 
nervous system indicates that autophagy can protect the host without altering viral replication, a 
mechanism that may be more relevant when discussing chronic inflammatory diseases [87]. 
The detailed discussion of how specific viruses negotiate the autophagy pathway is extensively 
discussed in the other reviews in this issue. Below, we have chosen to highlight several Crohn’s 
disease susceptibility genes because they have been demonstrated to have functions related to the 
autophagy pathway (Table 1). These genes are not necessarily essential for autophagy and  can 
contribute to intestinal inflammation through unrelated mechanisms. Moreover, even genes that are 
essential for autophagy can participate in host defense in the absence of a double-membraned vesicle 
as seen with IFNγ-mediated destruction of Toxoplasma gondii, TLR-mediated phagosome maturation, Viruses 2011, 3   
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and innate immune recognition of double-stranded DNA [88-90]. Therefore, the following genes are 
related to the autophagy pathway but can contribute to inflammatory bowel disease independently of 
an autophagosome. 
Table 1.  Genes related to the autophagy  pathway associated with inflammatory bowel 
disease. The association between inflammatory bowel disease and the genes below the 
divider  requires further validation. The right column indicates if a gene has been 
demonstrated to function in an antiviral response. 
Autophagy 
Gene 
Function 
Antiviral 
Response 
ATG16L1 
Essential for autophagosome formation, 
suppressing inflammasome activity, and 
maintaining Paneth cells. 
Yes 
NOD2 
Induces cytokine expression and autophagy in the 
presence of muramyl dipeptide from the bacterial 
cell wall. 
Yes 
IRGM 
Small anti-microbial GTPase that regulates 
autophagy. 
Yes 
XBP1 
Leucine rich repeat protein associated with 
Parkinson’s disease and autophagosome 
maturation. 
? 
LRRK2 
Leucine rich repeat protein associated with 
Parkinson’s disease and autophagosome 
maturation. 
Yes 
VAMP3 
V-SNARE involved in fusion of MVBs to 
autophagosomes and other membrane trafficking 
events. 
Yes 
STAT3 
Transcription factor downstream of cytokine and 
growth factor receptors that can inhibit autophagy. 
Yes 
DAP 
A substrate of mTOR that negatively regulates 
autophagy. 
? 
ULK1 
A kinase that is part of a major regulatory complex 
directly upstream of autophagy. 
? 
TLRs 
Immune receptors that recognize conserved 
structures found in pathogens. Their activity can 
sometimes depend on autophagy. 
Yes 
 
3.1. ATG16L1 
The first indication that the autophagy pathway contributes to Crohn’s disease came from three 
GWAS published close together that implicated a common Threonine to Alanine substitution (T300A) 
in ATG16L1 [91-93]. ATG16L1 encodes a protein that forms a complex with ATG5 and ATG12 that Viruses 2011, 3   
 
 
1288 
catalyzes and specifies the location of LC3 lipidation, an event that is essential for conventional 
autophagy [94-96]. Atg16L1
−/− mice die soon after birth similar to mice deficient in other essential 
autophagy genes [96]. Macrophages isolated from these mice display enhanced inflammasome activity 
and overproduce IL-1β and IL-18 in response to LPS [96]. As a result of this increased capacity to 
produce active IL-1β and IL-18, irradiated mice reconstituted with Atg16L1
−/− bone marrow show 
increased inflammation and lethality in response to dextran sodium sulfate (DSS) treatment, a model of 
chemically-induced colitis. Inflammasome activation can be  enhanced by the increased reactive 
oxygen species (ROS) produced by damaged mitochondria that accumulate in the absence of 
functional autophagy [96-99], and a similar role for autophagy has been proposed in limiting type I 
IFN production downstream of viral infection [100,101]. 
Another Atg16L1-mutant mouse model was generated through gene-trap mutagenesis, a technique 
in which introduction of a false splice acceptor into an intron disrupts the expression of intact   
mRNA [102]. Mice with such mutations in the Atg16L1 locus display decreased Atg16L1 protein 
levels and reduced autophagy but are viable [95]. These Atg16L1
HM (HM for hypomorph) mice have 
specific abnormalities in Paneth cells, specialized epithelial cells located at the base of the small 
intestinal crypts. Paneth cells are considered important for innate immunity as they package 
antimicrobial molecules into secretory granules,  and  they  are also essential for maintaining the 
intestinal stem cell niche [103,104]. Paneth cells from Atg16L1
HM mice are morphologically aberrant, 
have defective granule formation and secretion, and overexpress inflammatory genes [95]. This 
observation in mice led to the finding that Crohn’s disease patients homozygous for the ATG16L1 risk 
polymorphism display similar abnormalities in their Paneth cells, indicating that Atg16L1 has a 
conserved role in this unique cell-type [95].  
Mice develop similar Paneth cell abnormalities when Atg5 or Atg7, two other autophagy genes, are 
conditionally deleted in the intestinal epithelium [95,105]. These results indicate that this cell-type 
specific role of Atg16L1 is related to the autophagy pathway and could be related to the damaged 
organelles that accumulate in mutant Paneth cells [95]. Although it is unclear  if the mechanism 
involves conventional autophagy and autophagosomes, the effect of Atg16L1-deficiency on Paneth 
cells and the inflammasome could not have been predicted by population genetic studies. Other 
Crohn’s disease susceptibility genes are likely to have cell-type, organ, or context-specific functions 
that remain to be uncovered. 
It is currently uncertain how the T300A substitution affects ATG16L1 function. This coding change 
occurs in a region that is not evolutionarily conserved and does not appear to be necessary for 
conventional autophagy [106,107]. In cell lines, ATG16L1 T300A impairs capture of Salmonella by 
autophagosomes, which suggests that this variant compromises xenophagy without altering starvation-
induced autophagy [106,108]. Further investigation will be necessary since these results were not 
replicated by another study using primary mouse fibroblasts [107]. 
3.2. NOD2 
Several groups have independently demonstrated that Nod2 can function in the autophagy pathway 
in addition to signaling cascades, thus bridging two major Crohn’s disease susceptibility   
genes [108-111]. MDP activation of Nod2 induces Atg16L1-dependent autophagy, but not in cells Viruses 2011, 3   
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expressing the disease variants of either of these susceptibility genes [108-110]. These studies 
demonstrate that this functional interaction between Atg16L1 and Nod2 is important for limiting 
intracellular bacterial replication as well as increasing MHC class II surface expression. Another group 
has shown that peripheral blood mononuclear cells (PBMCs) expressing the T300A risk allele of 
ATG16L1 overproduce IL-1β in the presence of MDP, although expression of a NOD2 risk variant 
prevents this IL-1β production altogether [111]. In contrast to LPS-mediated overproduction of IL-1β 
in mouse Atg16L1
−/− macrophages, this process does not appear to involve enhanced inflammasome 
activity, and many outstanding questions remain. 
These studies are immensely important because they begin to address the relationship between 
Crohn’s disease susceptibility genes. In the next step, such gene-gene interactions must be further 
examined in the setting of intestinal mucosal immunity. A commonly discussed model of Crohn’s 
disease is one in which individuals are genetically susceptible to a pathogen that triggers a 
compensatory and harmful immune response. Anti-bacterial autophagy through Atg16L1, Nod2, and 
potentially other autophagy-related genes is consistent with this model. However, one of the strongest 
experimental support for this model comes from an unrelated study using Citrobacter rodentium to 
induce intestinal inflammation in Nod2
−/− mice [112]. During C. rodentium infection, colonic stromal 
cells produce the chemokine CCL2 that is necessary to recruit inflammatory monocytes to the 
intestine. At first, Nod2
−/−  mice experience less inflammation because Nod2  is essential for the 
production of CCL2 by the stromal cells, and therefore inflammatory monocytes are not present. At 
later time points, the intestinal inflammation becomes significantly more severe and longer-lasting 
compared to control mice since the monocytes did not help clear the pathogen earlier [112]. At least 
superficially, this mechanism does not appear to be related to autophagy. Despite the well-performed 
cell culture experiments linking various Crohn’s disease genes to xenophagy or other  autophagy-
mediated processes, each of these genes must be thoroughly examined in vivo, especially in the context 
of infectious disease and commensal bacteria. 
3.3. IRGM 
IRGM is a member of the antimicrobial immunity-related GTPase family (also called p47 GTPases) 
family that can induce autophagy and was first linked to Crohn’s disease by GWAS [91,113]. Further 
mapping revealed a large 20 kb deletion of a regulatory region upstream of the coding region that is in 
strong linkage with the disease [114]. The effect of this deletion on the level of IRGM expression 
differs among various tissues and cell lines, thus underscoring the need for context-dependent 
experiments. Instead of an upstream deletion, a recent study suggests that a SNP in IRGM is the true 
Crohn’s disease risk factor [115]. The authors propose that this polymorphism prevents   
down-regulation by a microRNA (miR-196) that is highly expressed in Crohn’s disease intestinal 
tissue. They further demonstrate that greater IRGM expression leads to both co-localization of 
adherent invasive E. coli with the autophagy machinery and increased intracellular survival of the  
bacteria [115]. This observation opposes other studies in which IRGM increases autophagosome or 
phagosome maturation and decreases survival of intracellular bacteria [116-122]. Also, this and other 
strains of E. coli  are more abundant in the mucosa of Crohn’s disease patients [123-129].  While Viruses 2011, 3   
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inconsistencies within the literature must be addressed, the observation that a SNP could alter miRNA 
recognition is novel. 
The ability of IRGM to induce autophagy and limit the replication of intracellular bacteria has been 
most extensively demonstrated with  Mycobacteria  [116-118,121]. Unexpectedly, IRGM enhances 
autophagy by inducing mitochondrial depolarization and can increase ROS production and cell death 
[118]. Its murine ortholog Irgm1 (Lrg-47) protects hematopoietic stem cells (HSCs) and CD4+ T cells 
from IFNγ-mediated cell death through a mechanism related to its autophagy function [121,122]. To 
relate these findings to Crohn’s disease, it will be critical to determine how human IRGM is regulated 
since it is not known to be IFNγ-responsive as seen with mouse Irgm1 [130]. Nevertheless, IRGM 
could regulate inflammation by either regulating intracellular pathogens or cellular homeostasis much 
like ATG16L1.  
3.4. XBP1 
Unlike the other genes discussed in this section, the functional association of X box-binding protein 
1  (Xbp1)  with intestinal inflammation came first and inspired analysis of its genetic linkage to 
inflammatory bowel disease. Xbp1 was identified as a transcription factor that regulates the expression 
of MHC-II and was subsequently shown to be an essential part of the unfolded protein response (UPR) 
pathway [131-134]. During ER stress, the Xbp1 messenger RNA undergoes Ire1-dependent splicing 
which is necessary for translocation into the nuclease where it regulates UPR gene expression   
[131-133].  Secretory cell-types appear to be particularly dependent on Xbp1 since the process of 
secretion  places a high burden on the ER. Xbp1  deletion prevents the proper function of 
immunoglobulin-secreting plasma B cells and digestive enzyme-secreting zymogenic cells in the 
stomach [135,136]. Also, Xbp1-deletion in the intestinal epithelium leads to apoptosis of secretory 
granule-producing Paneth cells and mucus-secreting goblet cells [137]. Remarkably, many of these 
mice display spontaneous small intestinal inflammation as well as a more severe response to   
DSS-induced colitis [137]. Based on these results in mice, the authors questioned whether human 
XBP1 is mutated in inflammatory bowel disease patients. Deep sequencing of the XBP1 locus in 1200 
Crohn’s disease and ulcerative colitis patients identified several rare variants that confer hypomorphic 
expression in vitro [137]. This genetic linkage is consistent with other studies [138-140].  
Considering the connection between ER stress and autophagy, it is interesting to note that Paneth 
cells are abnormal in the absence of both  autophagy  and  Xbp1.  ER stress triggers autophagy to 
maintain homeostasis, and inhibiting autophagy can lead to ER abnormalities [141-144]. Therefore, 
altered  Xbp1  and  Atg16L1  function can theoretically lead to intestinal disease through the same 
mechanism. However, Xbp1 deletion leads to Paneth cell death, an outcome that is more severe and 
distinct when compared to Atg16L1  hypomorphism or Atg5/Atg7  deletion  [95,105,137].  For these 
reasons, functions of Xbp1 that are unrelated to autophagy will also be of interest when investigating 
intestinal inflammation. 
3.5. Toll-Like Receptors 
Toll-like receptors (TLRs) are a class of transmembrane receptors that recognize a variety of 
conserved structures found in microbes. Several risk variants in TLR1, 2, 4, 5, 6, and 9 have been Viruses 2011, 3   
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described, though these genes have not been associated with inflammatory bowel disease in the 
comprehensive genome wide association studies. One explanation for this discrepancy is that TLR 
variants influence severity and symptoms rather than predicting the general risk of developing disease 
[145]. For instance, ulcerative colitis patients are more likely to present inflammation that spreads 
throughout the large intestine if they carry certain polymorphisms in TLR1 and 2 [146]. A detailed 
discussion is beyond the scope of this review, but there is no doubt that multiple TLRs have essential 
functions in homeostasis, cancer, and immunity in the gastrointestinal tract [147-150]. Local 
stimulation of TLRs in the intestine with viral or bacterial ligands can have a profound effect on 
systemic antiviral immunity [151]. TLRs also have a complex relationship with the autophagy pathway 
that could be important in intestinal disease. Like NOD2, stimulation of some TLRs such as   
LPS-activation of TLR4 can induce autophagy [152], and as previously mentioned, autophagy genes 
regulate the function of TLR4 and other TLRs [89,96,153]. Since the molecular mechanism is 
becoming apparent in some examples [154], it will be possible to disrupt the intersection between 
TLRs and autophagy to test specific models. Collectively, this large body of literature indicates that 
TLRs integrate signals from multiple sources in the intestinal environment and shapes immunity at the 
cellular level. 
3.6. Other Autophagy-Related Genes 
The following autophagy-related genes have been tentatively linked to inflammatory bowel disease 
by one SNP in a non-coding region. The first two are associated with autophagy due to their potential 
involvement in trafficking of the autophagosome. Leucine rich repeat kinase 2 (LRRK2) is associated 
with Crohn’s disease through a GWAS meta-analysis [155] but a nearby gene (MUC19 which encodes 
a mucin) is as likely to be the gene of interest. Mutations in LRRK2 are implicated in Parkinson’s 
disease (PD) [156,157], possibly due to a role for this gene in autophagy-mediated clearance of protein 
aggregates in neurons [158]. Deletion of LRRK2 or expression of Parkinson’s disease mutants leads to 
increased autophagosomes and protein aggregates [158,159]. One study strengthened the argument that 
LRRK2 is a Crohn’s disease gene by demonstrating that this gene is regulated by IFNγ and expressed 
in immune cells in the mucosa of patients [160]. A SNP near VAMP3, which encodes a V-SNARE, is 
also a risk factor for Crohn’s disease [14]. In the autophagy pathway, VAMP3 was reported to mediate 
the specific fusion of multi-vesicular bodies (MVBs) with autophagosomes [161]. Further functional 
examination of this protein could yield a general role in cellular immunity since VAMP3-positive 
compartments are involved in phagocytosis of HIV and Mycobacteria  [162,163]. The autophagy 
pathway requires many of the same proteins utilized by other membrane trafficking events [164,165], 
and understanding how LRRK2  and  VAMP3  regulate  autophagy  or mucosal immunity appears 
important regardless of their significance in Crohn’s disease.  
The three remaining genes influence autophagy through upstream signaling events. Signal 
transducers and activators of transcription (STAT3)  is  associated with Crohn’s disease by a meta-
analysis of GWAS [14]  and encodes  a nuclear transcription factor that regulates gene expression 
downstream of several cytokine and growth factor receptors that are critical for immunity including 
IL-23R  [166]. A siRNA screen revealed that STAT3 limits autophagy in an mTOR independent 
fashion [167], and autophagy may be involved in STAT3 activation as well [168]. Death associated Viruses 2011, 3   
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protein (DAP or DAP1) has been linked with ulcerative colitis rather than Crohn’s disease [169], and 
encodes  a ubiquitously expressed protein originally identified in a screen for factors involved in   
IFNγ-induced apoptosis [170,171]. Recently, DAP1 was shown to be phosphorylated and inhibited by 
mTOR under nutrient rich conditions. In contrast, during nutrient starvation when mTOR is inactive, 
DAP1 becomes dephosphorylated and acts as a negative regulator to prevent uncontrolled autophagy 
[170,171]. Finally, a recent study specifically examining autophagy gene loci found a  SNP in   
Unc-51-like kinase-1 (ULK1) to be present more frequently in Crohn’s disease patients [172]. ULK1 is 
suppressed by mTOR, but unlike DAP1, signals the activation of autophagy as part of a larger complex 
[173,174]. It will be important to determine if these are bona fide susceptibility genes since signaling 
events upstream of autophagy may be easier to target pharmacologically. 
4. Virus-plus-susceptibility Gene Interaction in Crohn’s Disease 
4.1. Common Pathogens Alter Disease Penetrance in Mice 
A novel association between a virus, an autophagy gene, and Crohn’s disease was revealed when 
the aforementioned Atg16L1
HM  mice were transferred to an enhanced barrier facility [47]. Before 
discussing the details, it is first necessary to understand the context in which this experiment was 
performed. Differences in rodent animal facilities are a notorious variable exemplified by studies on 
the role of IL-10 in intestinal disease. IL-10 is a pleiotropic anti-inflammatory cytokine expressed by 
several different cell-types  [175-178].  Mice deficient in IL-10  or a subunit of the IL-10 receptor 
display highly variable spontaneous intestinal inflammation, and the severity depends on the animal 
facility in which they are kept [175]. One reason why inconsistencies exist between different animal 
facilities  is  due to  the presence of one or more infectious agents. In support of this hypothesis, 
intestinal disease in IL-10-deficient mice can be exacerbated by intentional infection with Helicobacter 
species that are commonly found in mouse colonies [179]. 
In addition to Helicobacter, the widespread prevalence of murine norovirus (MNV) has become 
evident. MNV was discovered when investigators observed that Stat1
−/− Rag2
−/− double mutant mice 
succumbed to death when tissue homogenates were injected intra-cerebrally  [180]. Sequencing 
analysis of the infectious material revealed the presence of a positive-sense RNA virus related to 
noroviruses that infect humans, viruses that are responsible for the majority of non-bacterial 
gastroenteritis [181]. It is likely that MNV was present in the mice at the onset of these experiments 
despite being kept in an animal facility where pathogens are actively monitored. After its discovery, 
multiple strains of MNV have been identified and shown to be present in many mouse colonies 
worldwide [182-185]. 
MNV has become a critical model for investigating the biology of noroviruses since the human 
viruses do not establish a productive infection in a genetically-tractable small animal model. However, 
the presence of MNV in mouse colonies has become a concern for those examining mucosal immunity 
especially because many strains persistently infect the gastrointestinal tract [185]. Atg16L1
HM mice 
were originally housed in a barrier facility known to harbor MNV (as it happens, the same facility in 
which the virus was discovered). To differentiate between experimental results that are dependent and 
independent of the presence of MNV, the Atg16L1
HM  mice were re-derived into an MNV-free Viruses 2011, 3   
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enhanced SPF facility by embryo transfer. Surprisingly, re-derived Atg16L1
HM mice do not display 
any of the Paneth cell abnormalities described in mice raised in the previous facility [47]. Upon oral 
inoculation with the laboratory strain MNV CR6, Atg16L1
HM but not control mice develop Paneth cell 
granule abnormalities as well as an altered gene expression profile (Figure 2). Interestingly, many of 
the genes that display differentially altered expression after 7 days of infection are associated with 
intracellular protein trafficking or amino acid metabolism, two processes related to autophagy. Since 
MNV infects macrophages and dendritic cells rather than the intestinal epithelium [47,186,187], one 
potential mechanism is that autophagy-deficiency renders Paneth cells sensitive to soluble factors 
released during MNV infection. As previously mentioned, a sophisticated stress response may be 
necessary to support granule production by this specialized cell-type, and autophagy is best known as a 
pathway to maintain cellular homeostasis.  
Figure 2. Atg16L1 mutation leads to Paneth cell abnormalities during viral infection. The 
small intestinal crypt contains several Paneth cells with antimicrobial granules (red circles) 
and intestinal stem cells (green). The response to murine norovirus (MNV) infection leads 
to Paneth cell abnormalities specifically in Atg16L1 mutant mice including depletion of 
granules, aberrant morphology, and altered gene expression. In contrast, MNV does not 
cause these changes in control mice. 
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4.2. An Autophagy Gene and a Virus Interact to Generate Intestinal Disease 
In addition to abnormalities in Paneth cells, MNV CR6 also mediates an aberrant intestinal injury 
response in Atg16L1
HM mice [47]. Dextran sodium sulfate (DSS) is a chemical that is commonly used 
to assess the intestinal injury response. In contrast to uninfected Atg16L1
HM mice or MNV-infected 
control mice, Atg16L1
HM mice infected with MNV CR6 develop several pathological hallmarks of 
Crohn’s disease after DSS treatment including villus blunting in the small intestine and transmural 
inflammation in the colon. Neutralizing TNFα  or IFNγ, two cytokines central to Crohn’s disease 
[188,189], can prevent this abnormal intestinal injury specific to MNV-infected Atg16L1
HM  mice. 
These pathologies are also prevented by broad-spectrum antibiotics treatment. These results indicate 
that the mechanism by which this virus-plus-susceptibility interaction generates disease in this model 
utilizes factors that are also important in human Crohn’s disease such as pro-inflammatory cytokines 
and commensal bacteria. 
This interaction between MNV CR6 and Atg16L1 mutation is remarkably specific. It is unlikely  
that all enteric infections will have this effect in Atg16L1
HM  mice since another strain of   
MNV (MNV CW3) does not trigger any of the Crohn’s-like abnormalities attributed to MNV CR6 
[47]. These two strains of MNV display 95% amino acid sequence identity across the genome. One 
explanation for this strain-specificity is that unlike MNV CR6, MNV CW3 is unable to establish a 
persistent infection. Therefore, it is possible that a continual immune response against an enteric virus 
is what mediates these Crohn’s-like pathologies. Why this aberrant immune response requires Atg16L1 
mutation is a critical question that must be addressed. Like the example with Sindbis virus [87], MNV 
replication is not altered in Atg16L1
HM mice, indicating that intracellular degradation of virions is not 
the explanation. Further investigation of the host response to MNV is likely to reveal novel 
mechanisms by which Atg16L1 contributes to immunity. 
4.3. Interpreting the Interaction Between MNV and Atg16L1 
The MNV-Atg16L1 interaction provides a specific example of how a pathogen and a susceptibility 
gene can combine to generate inflammatory bowel disease. Such results in a model organism do not 
necessarily indicate that an enteric virus directly triggers Crohn’s disease in humans. Without further 
evidence, we must resist the temptation to associate an agent that causes acute gastroenteritis with a 
disease that features chronic gastroenteritis. Epidemiological studies that have looked at an association 
between infectious gastroenteritis and inflammatory bowel disease show promising results but are far 
from conclusive [25,28,44-46]. Nonetheless, the ability of MNV to trigger Crohn’s-like pathologies in 
a mouse model reinforces the need to carefully examine a potential role of viruses in Crohn’s disease 
patients. A major role of viruses may explain why antibiotics and probiotics have had limited success 
in treating patients.  
The most important lesson from the Atg16L1
HM mice is not the potential identity of a virus in 
Crohn’s disease, but the possibility that an infectious trigger is genotype-specific. MNV CR6 infection 
does not lead to Paneth cell and DSS-induced abnormalities in control mice and many other mutant 
mouse strains [47,190]. If these results reflect the pathophysiology of human Crohn’s disease, then an 
individual pathogen or gene may display only poor association with disease incidence and severity. Viruses 2011, 3   
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Additionally, while the end result (intestinal inflammation) could be similar among patients, the route 
towards disease may differ between individuals. For instance, mice deficient in the Crohn’s disease 
gene Nod2 develop intestinal pathologies after infection with Helicobacter hepaticus or Citrobacter 
rodentium  [112,191]. Although the effect of MNV CR6 in these mice need to be examined, it is 
possible that different Crohn’s disease susceptibility genes interact with unrelated pathogens  to 
mediate intestinal pathologies. In this disease model, finding one specific causative agent would be 
difficult. Since different Crohn’s disease patients have a distinct set of gene variants, it stands to reason 
that patients may have been exposed to a distinct set of pathogens as well. 
5. Commensal Bacteria 
5.1. Crosstalk Between MNV and Bacteria 
Any model in which a virus triggers or exacerbates inflammatory bowel disease must consider the 
large body of work implicating bacteria in the disease [6]. In the above example in which MNV 
induces abnormalities in Atg16L1 mutant mice, the virus mediates disease through commensal bacteria 
[47]. Viral infection could alter the composition of commensal bacteria, potentially by inhibiting the 
ability of Paneth cells to secrete antimicrobial molecules. The Atg16L1
HM model would be a useful 
system to determine if a specific bacterial species or intestinal bacteria in general mediate disease 
downstream of a gene-environment interaction. The answer to this question has practical implications 
for the use of antibiotics to treat inflammatory bowel disease. There is already evidence that genotype 
can alter responsiveness to antibiotics during recurrent Crohn’s disease [192].  
Another relevant observation in a mouse model is that MNV infection promotes inflammation and 
lethality to secondary bacterial infection [193]. In this study, type I IFN produced in response to MNV 
infection potentiates Nod1 and Nod2 activity that leads to an exaggerated and harmful response to E. 
coli. Additionally, co-infection with MNV and Helicobacter bilis exacerbates intestinal inflammation 
in Mdr1a
−/− mice [194]. Mdr1a encodes a transmembrane transporter expressed by intestinal epithelial 
cells, and Mdr1a
−/− mice develop spontaneous intestinal inflammation possibly due to an inability to 
clear toxins [195]. The effect of MNV infection alone in Mdr1a
−/−  mice has not been carefully 
examined, but this observation is consistent with the ability of MNV to mediate inflammation in 
conjunction with bacteria. Co-infection with MNV and Helicobacter  species is likely a common 
occurrence in mouse colonies, and yet spontaneous intestinal inflammation is rare. The evidence thus 
far suggests that MNV has evolved to innocuously co-exist with the intestinal bacterial flora unless 
host immunity is compromised by secondary bacterial challenge or genetic deficiency, in which case 
virus-bacteria interactions can  become pathogenic. This property of MNV resembles the selective 
ability of Helicobacter  and  Bacteroides  species to mediate intestinal disease in specific genetic 
backgrounds [13,179]. The hypothetical viral, bacterial, parasitic, or fungal pathogens that mediate 
Crohn’s disease may have similarly co-evolved with humans.  
5.2. Relationship Between Viruses and Bacteria in Intestinal Disease 
Are there other examples in which commensal bacteria mediate disease downstream of a viral 
infection? Although experimental evidence of this concept may be new to Crohn’s disease research, Viruses 2011, 3   
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crosstalk between viruses and bacteria in other pathogenic situations have been documented. Chronic 
immune activation is a characteristic abnormality associated with HIV infection, the degree of which is 
strongly correlated with disease progression [196]. Systemic immune activation stems from circulating 
microbial  products that are derived from commensal bacteria that breach the intestinal   
epithelium [197]. A breakdown in intestinal barrier function is a hallmark of inflammatory bowel 
disease [198] and a realistic mechanism by which a virus could trigger intestinal disease; HIV infection 
is  frequently associated with gastrointestinal dysfunction [199]. Additionally, changes in the 
composition of commensal bacteria can be detected in macaques that develop colitis after infection 
with simian immunodeficiency virus (SIV) [200]. These pioneering observations with HIV and SIV 
necessitate similar experiments with other viruses. 
In addition to an effect of viral infection on commensal bacteria, the composition of commensal 
bacteria can influence the pathogenicity of a virus. Depletion of gram-positive bacteria with neomycin 
diminishes transcription of IL-1β/IL-18 and the subsequent adaptive immune response to   
influenza  [151]. A remarkable aspect of this observation is that other antibiotics (vancomycin, 
ampicillin, or metronidazole) have a significantly less pronounced effect indicating that certain 
bacteria are more important than others for supporting antiviral immunity. Since influenza infection 
can lead to a catastrophic secondary infection with Streptococcus pneumoniae [201], it will be equally 
important to examine if influenza infection can alter the host’s ability to tolerate intestinal bacteria. 
5.3. Autophagy and Commensal Bacteria 
Observations made in the Atg16L1
HM  mouse model provide an in vivo  example of a crosstalk 
between the autophagy pathway and commensal bacteria. In vitro experiments also indicate that there 
is such a relationship. A modest increase in adherent-invasive E. coli  replication can be detected 
during siRNA-mediated knock-down of Atg16L1  [120], raising the possibility that autophagy 
deficiency could favor the expansion of certain bacteria in the intestine. The autophagy pathway could 
also be important in dampening inflammatory responses to non-invasive intestinal bacteria. In addition 
to LPS, increased production of IL-1β in Atg16L1
−/− macrophages can be induced with commensal 
bacteria such as E. coli,  Enterobacter aerogenes, and Klebsiella pneumonia [96]. This abnormal 
cytokine response to these common  gram-negative bacteria may explain why chimeric Atg16L1
−/− 
mice or MNV-infected Atg16L1
HM  mice are susceptible to DSS treatment [47,96]. The increasing 
evidence linking the autophagy pathway to Crohn’s disease should motivate investigators to further 
examine the role of autophagy genes in controlling endogenous intestinal bacteria. 
6. Concluding Remarks 
We have summarized the current epidemiological, genetic, and experimental evidence supporting a 
role for viruses and/or autophagy in Crohn’s disease. However, it is important to avoid 
generalizations—a mechanism that applies to one Crohn’s disease patient may not be valid for another 
patient. We predict that if viruses that trigger Crohn’s disease exist, this will only be true for 
individuals of a certain genetic background as seen in the Atg16L1
HM  example in mice. This 
hypothesis is consistent with the opposing roles of Nod2 and Atg16L1 downstream of viral infection 
[47,193]. Similarly, whether it is xenophagy, organelle homeostasis, or a non-canonical function, the Viruses 2011, 3   
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contribution of the autophagy pathway to Crohn’s disease will only apply to a subset of individuals. 
The promise of individual-based therapy relies on understanding individual-based disease mechanism. 
With this caveat in mind, we wish the reader to consider the following. Although Crohn’s disease 
patients may be susceptible to pathogens [202], this susceptibility is dissimilar in both extent and 
outcome when compared to truly genetically immuno-compromised individuals [203]. While 
autophagy can degrade intracellular pathogens in some situations, especially in cell culture, autophagy 
is definitely essential for maintaining cellular homeostasis in many physiological circumstances. We 
propose that if there is a relationship between autophagy and viruses in Crohn’s disease, then 
autophagy is most likely protecting the host against an over-exuberant response to a viral infection 
rather than directly suppressing virion production. If correct, then investigators should not expect to 
find a virus that consumes the host. Instead, an effort should be placed to search for signatures of an 
aberrant response to a viral infection, perhaps a response that can be targeted therapeutically. 
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